Physician profile
Brian S Neely
NPI 1760479257
$4,867.93
in general payments reported to CMS, 2019-2025
38 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $346 · 2021: $779 · 2022: $694 · 2023: $484 · 2024: $729 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $792.90 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $775.89 | 2021-2025 | |
| Novo Nordisk INC | $712.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.70 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $329.26 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $261.20 | 2022-2025 | |
| Pfizer INC. | $216.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $147.32 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $130.54 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.27 | 2020-2023 | Trintellix |
| Abbott Laboratories | $87.24 | 2022-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $68.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $67.16 | 2020-2025 | Ajovy |
| Esperion Therapeutics, INC. | $60.67 | 2021-2024 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $57.89 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Neely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.